How Direct-Acting Antivirals Are Transforming Hepatitis C Care in Saudi Arabia: Insights From a 2016–2023.
Published in General & Internal Medicine
Hepatitis C virus (HCV) infection has long been a major global health burden, historically associated with chronic liver disease, cirrhosis, and hepatocellular carcinoma. For years, interferon-based therapies were the backbone of treatment yet they were difficult to tolerate, required long treatment durations, and produced inconsistent cure rates.
The introduction of direct-acting antivirals (DAAs) changed the landscape entirely. DAAs offer cure rates exceeding 95%, shorter treatment durations, improved safety profiles, and greater accessibility. Yet, despite these advances, Saudi Arabia has faced a lack of large-scale real-world data describing the clinical impact of DAAs on local HCV patients.
A recent retrospective study from 2016–2023 helps fill this gap and provides encouraging evidence for both clinicians and policymakers.
Study Overview
Researchers analyzed 144 Saudi HCV patients treated with DAAs in an outpatient setting over a seven-year period (2016–2023). The study focused on:
-
Genotype distribution.
-
Treatment response.
-
Biochemical improvements.
-
Trends in HCV incidence.
This real-world cohort provides valuable insights into treatment success and epidemiological shifts in HCV within the country.
Key Findings
1. 100% Sustained Virologic Response (SVR) Achieved
All 144 patients (100%) achieved SVR meaning their viral load became undetectable after treatment. This remarkable outcome highlights the reliability and potency of modern DAAs.
2. Genotype Distribution
The genotype breakdown revealed:
-
38.9%: Genotype 4 (GT4) the most prevalent genotype in the region.
-
20.1%: GT1.
-
6.3%: GT2.
-
5.6%: GT3.
-
29.2%: Unknown genotype.
The high proportion of unknown genotypes underscores a need for expanded genotyping capacity, although many DAAs remain effective regardless of genotype.
3. Significant Improvement in Liver Enzymes
After treatment, patients showed marked biochemical improvement:
-
ALT, AST, ALP → Significant reduction (p = 0.000).
-
Conjugated bilirubin → No significant change.
These improvements reflect reduced liver inflammation and confirm the therapeutic impact of DAAs beyond viral suppression.
4. A 77% Reduction in HCV Incidence Over Seven Years
Between 2016 and 2023, HCV incidence in the studied population fell from 0.54% to 0.12%—a dramatic 77% decline.
This trend likely reflects:
-
Successful DAA implementation.
-
Improved screening.
-
Better public health awareness.
-
Possibly reduced transmission through medical and non-medical exposures.
Why These Findings Matter
Clinical Implications
-
DAAs are highly effective across diverse genotypes.
-
Rapid improvement in liver function parameters supports earlier treatment.
-
Universal SVR rates reinforce their use as the standard of care.
Public Health Impact
-
The significant drop in incidence suggests meaningful progress toward viral elimination.
-
Data may guide national strategies under WHO’s HCV elimination goals for 2030.
-
Understanding genotype patterns helps in resource planning and drug procurement.
Future Directions
Although the results are promising, long-term questions remain:
-
How durable is SVR over decades?
-
What is the residual risk of HCC in cured patients with advanced fibrosis?
-
Can screening programs be further optimized?
-
What additional strategies can push incidence even lower?
Further research especially multicenter and prospective studies will help refine treatment pathways and strengthen Saudi Arabia’s national hepatitis control efforts.
Conclusion
This seven-year retrospective study provides solid evidence that DAA therapy is highly effective for Saudi HCV patients, achieving universal cure rates and significantly improving liver health. Coupled with the striking decline in HCV incidence, these findings emphasize the transformative impact DAAs are having in the region.
As Saudi Arabia continues to expand access to antiviral therapy and enhance screening initiatives, it is well-positioned to move closer to the goal of eliminating hepatitis C as a public health threat.
Authors:
Fatimah Salem Alayidh, Alexander Woodman, Nawaf Yahya Zakary, Rehab Yusuf Al-Ansari, Sharjeel Chaudhry, Amal Omar Alsaadi, Khadijah Ahmad Alharbi, Batool Abdullah Alamri, Shahad Mousa Alhomud, Shahad Hassan Albather, Sarah Abdullah Bataweel, Nouf Ahmed Madkhali, Samira Jamaan Alzahrani, Zarmina Ehtesham.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Infectious disease management in infants and children
BMC Infectious Diseases invites submissions for a Collection on Infectious diseases in infants and children.
Infectious diseases in infants and children represent a significant burden on healthcare systems globally, often leading to serious complications, long-term health issues, and even mortality. This Collection aims to explore the diverse range of infectious diseases that specifically affect the pediatric population, including but not limited to respiratory infections, gastrointestinal infections, and vaccine-preventable diseases. Understanding the unique immune responses and vulnerabilities of young children is crucial for developing effective prevention and treatment strategies tailored to their needs.
The continued research into pediatric infectious diseases is vital for several reasons. Advances in immunization have significantly reduced the incidence of many vaccine-preventable diseases; however, challenges remain, particularly with the emergence of antimicrobial resistance and the resurgence of certain infections. Furthermore, the COVID-19 pandemic has underscored the importance of infection control measures in childcare, preschool, and school settings and highlighted the need for ongoing surveillance of childhood diseases. This area of research promises to contribute to improved health outcomes for infants and children worldwide.
With sustained research efforts, we can anticipate significant advances in the future, including the development of novel vaccines, improved diagnostics, and tailored treatment protocols. Continued exploration of the epidemiology of childhood diseases will further enhance our understanding of transmission dynamics and inform public health interventions.
We invite pediatricians, infectious disease specialists, public health professionals, immunologists, epidemiologists, and researchers in related fields to contribute original research articles on topics including but not limited to:
- Pediatric infectious diseases and their management
- Early childhood immunity and its implications
- Epidemiology of respiratory infections in children
- Antimicrobial resistance trends in pediatric settings
- Infection control in childcare, preschool, and school settings
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 30, 2026
Hepatitis virus infections and treatment
BMC Infectious Diseases invites submissions for a Collection on Hepatitis virus infections and treatment.
Hepatitis virus infections—including types A, B, C, D, and E—remain a significant global public health concern, collectively affecting hundreds of millions of people and contributing to a wide spectrum of liver-related diseases. These range from acute hepatitis and chronic liver inflammation to cirrhosis and hepatocellular carcinoma. Each hepatitis virus presents unique challenges in terms of transmission, disease progression, and treatment, with varying impacts across different regions and populations.
While hepatitis C has seen transformative progress with the development of Direct-Acting Antivirals (DAAs), hepatitis B continues to pose challenges due to its chronic nature and the need for lifelong management. Hepatitis A and E, typically transmitted via the fecal-oral route, are preventable through improved sanitation and vaccination, yet outbreaks still occur in resource-limited settings. Hepatitis D, which only occurs in conjunction with hepatitis B, adds complexity to diagnosis and treatment strategies.
Recent advances in diagnostics, therapeutics, and public health interventions have improved outcomes for many affected individuals. However, disparities in access to care, limited awareness, and gaps in screening and vaccination programs hinder global efforts to eliminate viral hepatitis as a public health threat. Continued research is essential to develop more effective prevention strategies, enhance treatment protocols, and understand the epidemiological and clinical nuances of each hepatitis virus. This Collection welcomes research that explores:
- Innovations in antiviral therapies across hepatitis types
- Epidemiology and transmission dynamics of hepatitis A–E
- Vaccine development and implementation strategies
- Novel diagnostic tools for acute and chronic hepatitis
- Public health approaches to hepatitis prevention and control
- Clinical implications of co-infections (e.g., HBV/HDV)
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 20, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in